Pharmacokinetics, Safety, and Tolerability of a Solution Formulation of LY3298176 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Tirzepatide (Primary) ; Tirzepatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 31 Jan 2019 Status changed from active, no longer recruiting to completed.
- 19 Sep 2018 Planned End Date changed from 30 Nov 2018 to 27 Dec 2018.
- 19 Sep 2018 Planned primary completion date changed from 30 Nov 2018 to 27 Dec 2018.